European licensing of maintenance treatment in schizophrenia

The Lancet

Volumn 380, Issue 9841, 2012, Pages 562-563

  Isaac, Maria ^a   Pani, Luca ^b   Gispen De Wied, Christine ^c   Koch, Armin ^a,d  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b ITALIAN MEDICINES AGENCY   (Italy)

^c MEDICINES EVALUATION BOARD   (Netherlands)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO;

CLINICAL TRIAL (TOPIC); HUMAN; LETTER; LICENSING; MAINTENANCE THERAPY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; RISK; SCHIZOPHRENIA; SUICIDE;

EID: 84864864591     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61327-0     Document Type: Letter

References (3)

1. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063-71.
2. CHMP. Clinical investigation of medicinal products in the treatment of schizophrenia (CPMP/EWP/559/95). http://www.emea.europa.eu/pdfs/human/ewp/ 055995en.pdf (accessed July 24, 2012).
3. Nutt D, Goodwin G. ECNP summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur Neuropsychopharmacol 2011; 21: 495-99.